スポンサーリンク
Yokohama City Univ. Kanagawa Jpn | 論文
- Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
- Site-specific incorporation of 4-lodo-L-phenylalanine through opal suppression
- A meta-analysis of ^F-Fluoride positron emission tomography for assessment of metastatic bone tumor
- Optimum emission time in deep-inspiration breath-hold PET-CT : a preliminary result
- FDG-PET of patients with suspected renal failure : standardized uptake values in normal tissues
- FDG-PET for the diagnosis of fever of unknown origin : a Japanese multi-center study
- Analysis of various malignant neoplasms detected by FDG-PET cancer screening program : based on a Japanese Nationwide Survey
- Assessment of tumor hypoxia by ^Cu-ATSM PET/CT as a predictor of response in head and neck cancer : a pilot study
- Polychlorinated Biphenyl/Biphenyl Degrading Gene Clusters in Rhodococcus sp. K37, HA99, and TA431 Are Different from Well-Known bph Gene Clusters of Rhodococci
- The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level
- Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
- Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine : a multicenter study
- Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma
- Evaluation of organ-specific glucose metabolism by ^F-FDG in insulin receptor substrate-1 (IRS-1) knockout mice as a model of insulin resistance
- Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET : results of a Japanese nationwide survey
- Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes